drugset

drugset / Trial / NCT05303259

Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury

NCT05303259 ↗

Phase 2 Unknown 204 enrolled Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

RandomizedParallel-groupSingle-blindTreatment

Summary

To investigate the effect of Bevacizumab on asymptomatic radiotherapy-induced brain injury patients with head and neck cancer.

Timeline

Start: 2021-11-01
Primary completion: 2024-12-30
Completion: 2025-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	2.5 mg/kg	—

Indications